- €11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024
- Positive results of the Phase 2-3 COVA study for the treatment of severe COVID-19 with Sarconeos (BIO101)
- Early Access Program (EAP) submission in France by June 2023 while preparing filing for conditional marketing authorization in the USA and Europe for Sarconeos (BIO101) in COVID-19
Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity
Biophytis today announces the completion of a capital increase through the issue of new shares, accompanied by share subscription warrants, with the removal of the preferential subscription rights of the…
